In these cases, an anti-EGFR with or without irinotecan is used in the third-line setting, followed by TFD/TPI with bevacizumab or regorafenib in later lines for human epidermal growth factor receptor 2 (HER2)-negative tumours and by anti-HER strategies for HER2-positive tumours. Here, EGFR is linked to neoplasm.